The continuity of telehealth services, especially the authority to prescribe controlled substances via telehealth to new patient-provider relationships which was due to expire on November 11, has been secured following its extension through the end of 2024, as stated by Burr & Forman.
The unprecedented demand for digital health services spurred by the Covid-19 pandemic has ignited a reassessment of telehealth regulations and policies. Telehealth prescribing, being a critical component of these services, emerged at the forefront of this reassessment. New rules and guidelines have been introduced periodically to manage prescribing practices, secure patient safety, and provide necessary care without any disruption.
The extension through 2024 is a significant move, demonstrating the steadfast commitment of policy makers to maintain the momentum of telehealth services and to ensure continued access to essential medical treatments. It also hints at the wider acceptance of telehealth in the future of healthcare delivery.
To better understand the impact of this extension and its role in shaping the future of telehealth regulations — particularly, the telehealth prescribing practices post the Covid-19 pandemic period, legal and health professionals are advised to follow the developments closely.
For a more detailed understanding please refer to the latest announcement by Burr & Forman on this topic, you can access it here.
This move could potentially redefine the landscape of telehealth services, particularly in the domain of prescription of controlled substances via telehealth, by providing a firmer regulatory structure and promoting a sustainable mix of digital and traditional healthcare models.
Looking forward, corporations and law firms involved in this field should proactively adapt to these evolving telehealth laws and consider them when strategizing for future business development.